1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jeil Pharmaceutical Co. Ltd.

Jeil Pharmaceutical Co. Ltd.

KKRX:271980
8,960.00
KRW
-90.00
(-0.99%)
1,497.32EPS
16.02P/E
150.14BMarket Cap
Jeil Pharmaceutical Co. Ltd.
KRX:271980
(Korea Stock Exchange)

Recent

price

8,960.00

P/E

ratio

16.02

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
25,358.98
47,137.68
45,768.43
47,280.35
47,973.91
49,543.02
49,783.37
48,359.92
38,933.82
37,182.16
Revenue per Share
72.86
142
-698
473
-854
-898
343
-2,057
1,605
637.4
Basic EPS, GAAP
-560.17
839.42
1,878.83
-1,498.65
938.51
-2,202.33
-997.63
-233.37
-1,013.54
-1,199.94
Free Cash Flow per Basic Share
- -
55.24
59.68
69.94
70
65.01
49.92
50
- -
- -
Dividend per Share
12,106.81
12,581.11
11,553.97
11,800.2
11,533.52
10,836.83
10,882.2
12,912.16
14,353.84
13,996.37
Book Value per Share
11,828.59
12,284.57
11,258.11
11,519.87
11,275.56
10,192.99
9,998.21
11,994.49
13,304.07
12,979.37
Tangible Book Value per Share
15
13
15
15
15
15
15
15
15
15
Basic Weighted Avg Shares
371,592
627,075
671,407
691,325
700,693
722,230
726,394
704,542
567,244
543,495
Sales/Revenue/Turnover
1.34
1.18
0.03
1.87
-1.48
-1.85
1.22
-2.63
3.7
0.75
Operating Margin (%)
3,863
6,625
7,747
8,993
9,133
8,886
9,767
11,297
12,317
12,863
Depreciation Expense
1,068
1,889
-10,239
6,916
-12,473
-13,091
5,005
-29,968
23,384
9,317
Net Income, GAAP
67.88
61.36
- -
44.51
- -
- -
- -
- -
8.44
- -
Effective Tax Rate (%)
0.29
0.3
-1.53
1
-1.78
-1.81
0.69
-4.25
4.12
1.71
Profit Margin (%)
92,146
78,800
55,615
59,455
62,729
22,984
-1,125
51,345
69,168
81,808
Working Capital
25,500
19,906
18,418
11,163
8,149
5,443
4,452
2,725
1,084
5,980
LT Debt
177,986
184,935
168,855
172,479
167,347
155,597
157,032
219,317
251,025
253,263
Total Equity
- -
1.25
- -
3.4
- -
- -
- -
- -
5.95
- -
Return on Invested Capital (%)
- -
1.08
- -
3.53
- -
- -
- -
- -
5.88
- -
Return on Capital (%)
- -
1.04
-5.79
4.05
-7.32
-8.03
3.16
-17.29
11.71
4.66
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
92,333
96,605
106,296
LT Borrowings
- -
- -
5,500
LT Finance Leases
1,084
771
480
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
222,779
205,133
150,137

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
311,621
323,422
330,246
Cash, Cash Equivalents & STI
58,832
66,959
67,407
Accounts Receivable, Net
136,848
137,646
146,534
Inventories
104,475
104,905
102,891
Total Current Liabilities
242,454
239,566
248,438
Payables & Accruals
- -
- -
- -
ST Debt
92,333
96,605
106,296
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.01%
14.46%
Free Cash Flow
- -
-58.75%
334.33%
Net Income, GAAP
- -
-258.09%
-178.03%
Sales/Revenue/Turnover
- -
-3.5%
-19.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
170,416
173,179
174,381
186,567
704,542
2025
163,024
137,628
134,761
131,831
567,244
2026
130,298
146,604
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-197
-1,819
-288
248.42
-2,057
2025
180
214
705.48
505.4
1,605
2026
-21.19
-545.23
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
50
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jeil Pharmaceutical Co.,Ltd Jeil Pharmaceutical Co.,Ltd develops, manufactures and supplies pharmaceutical products primarily in South Korea. The company offers prescription and over-the-counter drugs in antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral and antihistamine therapeutic areas; solid medicines and injections; finished dosage forms including patches such as Kefentech Plaster (Ketoprofen) and active pharmaceutical ingredients such as Cefditoren Pivoxil and Epinastine HCl; anti-inflammatory painkillers, anticancer drugs, gastritis drugs, ulcer treatments, antidepressants, pollakisuria and incontinence treatments, impetigo drugs, septicemia treatments, hyperlipidemia treatments, peripheral neuropathic pain drugs and hypertension drugs. Jeil Pharmaceutical operates factories and R&D centers in Yongin-si, Gyeonggi-do; exports finished products and APIs to over 40 countries in ASEAN, Central and South America, Africa, Japan and China; and maintains a nationwide medical representative organization supplying over 70 prescription drugs and 30 over-the-counter drugs domestically. Founded in 1959 and headquartered in Seoul, the company listed on KOSPI in 1988 and employs approximately 943-1143 people with annual sales exceeding KRW 680 billion. Recent developments include a June 2024 general pharmaceutical sales agreement between affiliate Jeil Health Science and Samsung Pharmaceutical; April 2024 memoranda of understanding with University of Malaysia Teaching Hospital and Malaysia National University of Medical Sciences for pharmaceutical supply and R&D collaboration; advancements in its drug pipeline such as domestic approval and licensing of JP-1366 for gastroesophageal reflux disease, alongside JPI-289 for stroke and JP-2266 for diabetes; and ongoing global expansion through strategic partnerships, licensing and open innovation with academic institutions and pharmaceutical firms.